Mereo BioPharma Stock Price

-0.12 (-4.03%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Mereo BioPharma Group PLC MREO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -4.03% 2.86 18:00:11
Close Price Low Price High Price Open Price Previous Close
2.86 2.78 2.965 2.96 2.98
Bid Price Ask Price Spread News
2.78 3.00 0.22 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
287 68,636 $ 2.87 $ 197,291 311,458 0.69 - 4.25
Last Trade Time Type Quantity Stock Price Currency
16:00:00 382 $ 2.86 USD

Mereo BioPharma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 193.74M 67.74M 67.74M $ - $ - -2.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Mereo BioPharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MREO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.083.182.782.99147,686-0.22-7.14%
1 Month3.213.422.45012.91266,250-0.35-10.9%
3 Months3.133.462.45012.97247,387-0.27-8.63%
6 Months0.94054.250.712.69257,3531.92204.09%
1 Year3.134.250.692.58207,025-0.27-8.63%
3 Years6.556.56590.692.62153,982-3.69-56.34%
5 Years6.556.56590.692.62153,982-3.69-56.34%

Mereo BioPharma Description

Mereo BioPharma Group PLC is a multi-asset biopharmaceutical company. It is focused on the acquisition, development, and commercialization of innovative therapeutics to improve outcomes for patients with rare and specialty diseases. The company portfolio consists of clinical-stage product candidates that include BPS-804 (setrusumab), AZD-9668 (alvelestat), BGS-649 (leflutrozole), OMP-313M32 (etigilimab), OMP-305B83 (navicixizumab) and BCT-197 (acumapimod).

Your Recent History
Mereo BioP..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.